Abstract
We examined allelic polymorphisms of the serotonin transporter (5-HTT) gene and antidepressant response to 6 weeks' treatment with the selective serotonin reuptake inhibitor (SSRI) drugs fluoxetine or paroxetine. We genotyped 120 patients and 252 normal controls, using polymerase chain reaction of genomic DNA with primers flanking the second intron and promoter regions of the 5-HTT gene. Diagnosis of depression was not associated with 5-HTT polymorphisms. Patients homozygous l/l in intron 2 or homozygous s/s in the promoter region showed better responses than all others (p < 0.0001, p = 0.0074, respectively). Lack of the l/l allele form in intron 2 most powerfully predicted non-response (83.3%). Response to SSRI drugs is related to allelic variation in the 5-HTT gene in depressed Korean patients.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Alleles
-
Antidepressive Agents / therapeutic use*
-
Carrier Proteins / genetics*
-
DNA / genetics
-
DNA / isolation & purification
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / genetics*
-
Depressive Disorder / psychology
-
Female
-
Genotype
-
Humans
-
Introns / genetics
-
Male
-
Membrane Glycoproteins / genetics*
-
Membrane Transport Proteins*
-
Middle Aged
-
Nerve Tissue Proteins / genetics*
-
Polymerase Chain Reaction
-
Polymorphism, Genetic
-
Promoter Regions, Genetic / genetics
-
Psychiatric Status Rating Scales
-
Selective Serotonin Reuptake Inhibitors / therapeutic use*
-
Serotonin Plasma Membrane Transport Proteins
Substances
-
Antidepressive Agents
-
Carrier Proteins
-
Membrane Glycoproteins
-
Membrane Transport Proteins
-
Nerve Tissue Proteins
-
SLC6A4 protein, human
-
Serotonin Plasma Membrane Transport Proteins
-
Serotonin Uptake Inhibitors
-
DNA